{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:46:48Z","timestamp":1790729208716,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2017.12.025","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T06:55:31Z","timestamp":1517900131000},"page":"S10-S20","source":"Crossref","is-referenced-by-count":167,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)"],"prefix":"10.1016","volume":"24","author":[{"given":"J.W.","family":"Baddley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"G\u00f3mez-Reino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"San-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Torre-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.12.025_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.12.025_bib2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A\u00a0metalloproteinase disintegrin that releases tumour-necrosis factor-\u03b1 from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2017.12.025_bib3","doi-asserted-by":"crossref","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","article-title":"Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases","volume":"22","author":"Billmeier","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cmi.2017.12.025_bib4","first-page":"243","article-title":"Advances in the development of new biologics in inflammatory bowel disease","volume":"29","author":"Ungar","year":"2016","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cmi.2017.12.025_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.intimp.2015.04.051","article-title":"Rheumatoid arthritis\u2014anti-TNF","volume":"27","author":"Chaabo","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.cmi.2017.12.025_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1871530315666150316121808","article-title":"TNF as a target of inflammation in rheumatoid arthritis","volume":"15","author":"Yamanaka","year":"2015","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.cmi.2017.12.025_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-016-3436-0","article-title":"Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies","volume":"36","author":"Elyoussfi","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cmi.2017.12.025_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.02.1221","article-title":"Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent","volume":"75","author":"Yamauchi","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib9","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/00003495-200565150-00014","article-title":"Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis","volume":"65","author":"Siddiqui","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.12.025_bib10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2165\/00003495-200565090-00006","article-title":"Infliximab: in ankylosing spondylitis","volume":"65","author":"Robinson","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.12.025_bib11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2165\/00003495-200767120-00005","article-title":"Infliximab therapy in children and adolescents with inflammatory bowel disease","volume":"67","author":"Veres","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.12.025_bib12","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s40265-015-0503-x","article-title":"Adalimumab: a review in chronic plaque psoriasis","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.12.025_bib13","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2165\/11470250-000000000-00000","article-title":"Adalimumab: in non-radiographic axial spondyloarthritis","volume":"72","author":"Burness","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.12.025_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/17425255.2016.1146682","article-title":"Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis","volume":"12","author":"Tanaka","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cmi.2017.12.025_bib15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/MIB.0b013e318280b169","article-title":"The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor \u03b1","volume":"19","author":"Ueda","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40264-015-0336-2","article-title":"Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"38","author":"Capogrosso Sansone","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.cmi.2017.12.025_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.cmi.2017.12.025_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.hoc.2010.11.009","article-title":"Infectious complications associated with immunomodulating biologic agents","volume":"25","author":"Koo","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.cmi.2017.12.025_bib19","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2017.12.025_bib20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cmi.2017.12.025_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cmi.2017.12.025_bib23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.bjp.0704549","article-title":"TNF ligands and receptors\u2014a matter of life and death","volume":"135","author":"MacEwan","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cmi.2017.12.025_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.cmi.2017.12.025_bib25","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2017.12.025_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.12.025_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2017.12.025_bib28","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3899\/jrheum.150057","article-title":"The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies","volume":"42","author":"Ai","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib29","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2017.12.025_bib30","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib31","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib32","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib34","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","article-title":"Serious infections during anti-TNF\u03b1 treatment in rheumatoid arthritis patients","volume":"8","author":"Favalli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cmi.2017.12.025_bib36","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib37","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cmi.2017.12.025_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","article-title":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japan","volume":"36","author":"Koike","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib42","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/s10165-011-0541-5","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients","volume":"22","author":"Koike","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib43","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3899\/jrheum.110373","article-title":"Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers","volume":"38","author":"Kim","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib44","first-page":"193","article-title":"Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis","volume":"8","author":"Alawneh","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.cmi.2017.12.025_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.150177","article-title":"Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: report from a large multicenter cohort with high background prevalence","volume":"43","author":"Kisacik","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.025_bib47","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cmi.2017.12.025_bib48","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"Lobue","year":"2010","journal-title":"Respirology"},{"issue":"54","key":"10.1016\/j.cmi.2017.12.025_bib49","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings","volume":"2005","author":"Jensen","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2017.12.025_bib50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib52","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2017.12.025_bib53","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/ajg.2016.433","article-title":"Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab","volume":"111","author":"Osterman","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2017.12.025_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.eimc.2015.11.021","article-title":"Guidelines for the use of interferon-\u03b3 release assays in the diagnosis of tuberculosis infection","volume":"34","author":"Santin","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cmi.2017.12.025_bib56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/ciu796","article-title":"Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study","volume":"60","author":"Munoz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cmi.2017.12.025_bib58","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","article-title":"Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases","volume":"74","author":"Hatzara","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib59","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2017.12.025_bib60","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","article-title":"Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"69","author":"Fouque-Aubert","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib61","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib62","first-page":"1333","article-title":"Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-\u03b1 inhibitors","volume":"60","author":"Zhang","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.cmi.2017.12.025_bib63","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib64","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2017.12.025_bib65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2017.12.025_bib66","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/BOR.0b013e3282f4b392","article-title":"The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib67","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib68","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib69","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib70","first-page":"653","article-title":"Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs","volume":"32","author":"Emery","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib71","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/cid\/ciu104","article-title":"Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae","volume":"58","author":"Novosad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib72","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1001\/jama.2011.1705","article-title":"Is anti-TNF therapy safer than previously thought?","volume":"306","author":"Dixon","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2017.12.025_bib73","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib74","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib75","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2013-204011","article-title":"Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy","volume":"74","author":"Yun","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib76","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/rheumatology\/keu255","article-title":"Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort","volume":"54","author":"Wallis","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2017.12.025_bib77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3899\/jrheum.140067","article-title":"The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts","volume":"43","author":"Haddad","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib78","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ajg.2012.464","article-title":"Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients","volume":"108","author":"Syed","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2017.12.025_bib79","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/bjs.9152","article-title":"The effect of immune therapy on surgical site infection following Crohn's Disease resection","volume":"100","author":"Serradori","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.cmi.2017.12.025_bib80","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/ibd.22954","article-title":"Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib81","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crohns.2013.01.014","article-title":"Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis","volume":"7","author":"Billioud","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cmi.2017.12.025_bib82","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00384-011-1236-2","article-title":"Anti-TNF-\u03b1 therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience","volume":"26","author":"Rizzo","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib83","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/apt.12159","article-title":"Pre-operative use of anti-TNF-\u03b1 agents and the risk of post-operative complications in patients with Crohn's disease\u2014a nationwide cohort study","volume":"37","author":"Norgard","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2017.12.025_bib84","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","author":"Colombel","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2017.12.025_bib85","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1463-1318.2010.02469.x","article-title":"Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?","volume":"13","author":"Canedo","year":"2011","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib86","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4240\/wjgs.v8.i3.274","article-title":"Post-operative abdominal complications in Crohn's disease in the biological era: systematic review and meta-analysis","volume":"8","author":"Waterland","year":"2016","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.cmi.2017.12.025_bib87","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib88","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib89","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/ard.2011.152769","article-title":"Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Galloway","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib90","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib91","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor \u03b1-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib92","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jama.2011.1387","article-title":"Growing list of infections linked to TNF blockers","volume":"306","author":"Kuehn","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2017.12.025_bib93","first-page":"854","article-title":"Listeria monocytogenes infection in patients with rheumatic diseases on TNF-\u03b1 antagonist therapy: the Spanish Study Group experience","volume":"26","author":"Pena-Sagredo","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib94","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.12-2820","article-title":"Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study","volume":"144","author":"Lanternier","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2017.12.025_bib95","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib96","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2017.12.025_bib97","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-\u03b1 agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2017.12.025_bib98","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib99","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/jid.2011.383","article-title":"Risk of herpes zoster in patients receiving anti-TNF-\u03b1 in the prospective French RATIO registry","volume":"132","author":"Serac","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib100","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garcia-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib101","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciu098","article-title":"Risk of stroke following herpes zoster: a self-controlled case-series study","volume":"58","author":"Langan","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mayocp.2015.09.015","article-title":"Risk of stroke and myocardial infarction after herpes zoster in older adults in a US community population","volume":"91","author":"Yawn","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2017.12.025_bib103","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.39855","article-title":"Herpes zoster and the risk of stroke in patients with autoimmune diseases","volume":"69","author":"Calabrese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib104","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ibd.20131","article-title":"Infliximab and the risk of latent viruses reactivation in active Crohn's disease","volume":"13","author":"Lavagna","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","article-title":"Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease","volume":"31","author":"Shale","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2017.12.025_bib106","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10620-010-1126-4","article-title":"Cytomegalovirus infection in patients with active inflammatory bowel disease","volume":"55","author":"Kim","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cmi.2017.12.025_bib107","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ard.2004.031187","article-title":"Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy","volume":"64","author":"Wendling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib108","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10620-005-1295-8","article-title":"Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B","volume":"50","author":"Ueno","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cmi.2017.12.025_bib109","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib110","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib111","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2017.12.025_bib112","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2012.63","article-title":"Management of rheumatic disease with comorbid HBV or HCV infection","volume":"8","author":"Vassilopoulos","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib113","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1136\/annrheumdis-2011-200163","article-title":"Let the fog be lifted: screening for hepatitis B virus before biological therapy","volume":"70","author":"Winthrop","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib114","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib115","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib116","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib117","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib118","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor \u03b1 antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib119","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3899\/jrheum.160983","article-title":"Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis C virus infection","author":"Burton","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib120","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2017.12.025_bib121","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib122","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/keh696","article-title":"Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis","volume":"44","author":"Torre-Cisneros","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2017.12.025_bib123","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/MIB.0000000000000412","article-title":"Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis","volume":"21","author":"Pillet","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib124","first-page":"530568","article-title":"Epstein\u2013Barr virus reactivation after infliximab in rheumatoid arthritis: a case report","volume":"2011","author":"Colaci","year":"2011","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib125","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.dld.2017.03.011","article-title":"Epstein\u2013Barr virus-positive mucocutaneous ulcer in Crohn's disease. A condition to consider in immunosuppressed IBD patients","volume":"49","author":"Juan","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib126","first-page":"2013","article-title":"EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?","author":"Allen","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cmi.2017.12.025_bib127","first-page":"1561","article-title":"Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab","volume":"29","author":"True","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib128","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1378\/chest.124.6.2395","article-title":"Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-\u03b1 therapy","volume":"124","author":"Hage","year":"2003","journal-title":"Chest"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.cmi.2017.12.025_bib129","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41","author":"Wallis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib131","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor \u03b1 antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib132","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.025_bib133","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cmi.2017.12.025_bib134","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/art.27735","article-title":"Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007","volume":"62","author":"Louie","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib135","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia under anti-tumor necrosis factor therapy study G. Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.025_bib136","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2017.12.025_bib137","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib138","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.140099","article-title":"Performance of the tuberculin skin test and interferon-\u03b3 release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches","volume":"91","author":"Goletti","year":"2014","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.cmi.2017.12.025_bib139","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1183\/13993003.01012-2016","article-title":"Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis","volume":"48","author":"Petruccioli","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2017.12.025_bib140","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2017.12.025_bib141","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic society\/infectious diseases society of America\/Centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib142","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.rdc.2016.09.012","article-title":"Hepatitis B reactivation in rheumatic diseases: screening and prevention","volume":"43","author":"Koutsianas","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.cmi.2017.12.025_bib143","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib144","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2017.12.025_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2017.12.025_bib146","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3899\/jrheum.091107","article-title":"Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists","volume":"37","author":"Bernatsky","year":"2010","journal-title":"J\u00a0Rheumatol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18300302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18300302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T21:35:27Z","timestamp":1559338527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18300302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":146,"alternative-id":["S1198743X18300302"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.12.025","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}